It is of interest that in our panel of cisplatin resistant NSCLC cell lines that displayed a significant increase in the number of CD133+ cells, there was a significant corresponding enrichment of the cancer stem cell marker, CD133, relative to that seen in parent cells. Here, PROM1 is linked to cancer.